The Pharma Data
MARCH 8, 2021
Since licensed by Ridgeback all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck. EIDD-2801 was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University. About Ridgeback Biotherapeutics.
Drug Discovery World
OCTOBER 16, 2023
Dr Tralau-Stewart says: “Indeed, many academic institutions have established new ways of supporting the discovery pipeline, providing tech transfer offices to support licensing, and entrepreneurship and start-up support through fundraising, accelerators, and incubators. appeared first on Drug Discovery World (DDW).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 5, 2020
Sussman has also had leadership experience in industry as the founder and vice president of both Amphioxus Cell Technologies from 1995 to 2003 and Hepatix, Inc. Most recently, Holland served as Global Head of licensing at Lonza AG. O’Day has been a principal investigator for more than 200 clinical trials. from 1993 to 1995.
Drug Target Review
FEBRUARY 28, 2024
Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers. from 2003 to 2006, covering the biotechnology and life-science tools sectors.
The Premier Consulting Blog
JANUARY 17, 2023
The Pediatric Research Equity Act (PREA) was signed into law in 2003 to increase pediatric use information in product labeling and close knowledge gaps regarding the safety, efficacy, and appropriate dosing of drugs to treat children.
The Pharma Data
FEBRUARY 25, 2021
Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac , its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older. 2003 Dec 12;22(2):217-23. NEW YORK–(BUSINESS WIRE)– Pfizer Inc.
New Drug Approvals
JULY 10, 2023
1] Zavegepant is an antagonist of the calcitonin gene-related peptide (CGRP) receptor currently in phase 3 trials in an intranasal formulation for the treatment of migraine. The clinical trial is expected to complete in September 2020. Zavegepant is indicated for the acute treatment of migraine with or without aura in adults. [1]
Expert insights. Personalized for you.
69 
Let's personalize your content